Court Blocks HHS Layoff and Restructuring Plans, Citing Overreach of Authority
Federal Judge Blocks Trump Administration’s Sweeping HHS Layoff and Reorganization Plan, Citing Lack of Legal Authority A federal judge in California has issued a significant legal blow to the Trump…
EU Recommends Approval of Eylea™ 8 mg with Extended 6-Month Dosing Interval
Bayer’s Eylea™ 8 mg Recommended for EU Approval with Extended 6-Month Treatment Interval for Major Retinal Diseases Bayer has today announced a significant milestone in the treatment of retinal diseases,…
CHMP Backs Blenrep Combos for Relapsed/Refractory Multiple Myeloma
GSK’s Blenrep Combinations Receive Positive CHMP Opinion for Relapsed or Refractory Multiple Myeloma, Signaling Expanded Access Across Europe In a significant step forward for the treatment of multiple myeloma, GSK…
NICE in England Recommends FILSPARI for the Treatment of IgA Nephropathy
NICE Recommends FILSPARI® (sparsentan) for Routine Use in the NHS to Treat Adults with IgA Nephropathy, Marking a Significant Step Forward in Rare Kidney Disease Management CSL Vifor has announced…
CVS Health Survey Reveals Smoking Trends Among Young Adults
Rethinking Nicotine: CVS Health Survey Uncovers Widespread Misconceptions About E-Cigarette Safety Among Young Adults Over the past few decades, the public conversation around tobacco and nicotine use has transformed dramatically.…
ASCENT-03: Trodelvy Significantly Improves PFS in First-Line mTNBC Patients Ineligible for Checkpoint Inhibitors
Trodelvy Marks Breakthrough in First-Line mTNBC Treatment with Positive Phase 3 ASCENT-03 Results Gilead Sciences has announced encouraging topline results from its Phase 3 ASCENT-03 clinical trial evaluating Trodelvy® (sacituzumab…
Bayer Launches Centafore Imaging Core Lab for Clinical Trials and SaMD Development
Bayer Launches Centafore Imaging Core Lab to Revolutionize Clinical Trial Imaging and SaMD Development Bayer, a global leader in healthcare and life sciences, today officially announced the launch of its…
Merck Highlights Cutting-Edge Advances in Treating Advanced Cancers and Rare Tumors at ASCO 2025
Merck Highlights Breakthrough Innovations in Advanced Cancers and Rare Tumors at ASCO 2025 Merck, a global leader in science and technology, has once again showcased its commitment to transforming cancer…
US FDA Grants Approval for Nucala (Mepolizumab) to Treat Adults with Chronic Obstructive Pulmonary Disease (COPD)
GSK’s Nucala (Mepolizumab) Receives US FDA Approval as Add-On Maintenance Treatment for Adults with Eosinophilic Phenotype COPD GSK has officially announced a significant milestone in the treatment of chronic obstructive…
Dr. Mark Stetter Joins Zoetis Board of Directors Following Election
Dr. Mark Stetter Elected to Zoetis Board of Directors, Bringing Decades of Veterinary Leadership and Animal Health Expertise Zoetis,a global leader in animal health, announced a significant addition to its…
Linvoseltamab Combos Show Early Promise in Relapsed/Refractory Multiple Myeloma
Regeneron’s Linvoseltamab Combinations Show Strong Early Signals in Relapsed/Refractory Multiple Myeloma in Phase 1b Trial Regeneron Pharmaceuticals,has reported encouraging early findings from the ongoing Phase 1b LINKER-MM2 study, evaluating linvoseltamab…
Bristol Myers Squibb to Showcase Oncology Pipeline and Research at ASCO 2025
Bristol Myers Squibb Showcases Expansive Oncology Portfolio and Groundbreaking Clinical Research at ASCO 2025 Annual Meeting Bristol Myers Squibb is set to make a significant impact at the 2025 American…